• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.基于人群的伴腋窝淋巴结转移隐匿性乳腺癌分析。
Cancer. 2010 Sep 1;116(17):4000-6. doi: 10.1002/cncr.25197.
2
Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.影响隐匿性乳腺癌伴腋窝淋巴结转移患者管理和预后的因素:国家癌症数据库分析。
Ann Surg Oncol. 2017 Oct;24(10):2907-2914. doi: 10.1245/s10434-017-5928-x. Epub 2017 Aug 1.
3
Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.对于选择保乳治疗或乳房切除术的年轻乳腺癌女性,腋窝管理因患者而异。
Breast Cancer Res Treat. 2020 Feb;180(1):197-205. doi: 10.1007/s10549-019-05520-5. Epub 2020 Jan 14.
4
Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.接受保乳治疗的T1-2期乳腺癌伴前哨淋巴结大转移患者腋窝的处理
J Invest Surg. 2019 Jan;32(1):48-54. doi: 10.1080/08941939.2017.1375051. Epub 2017 Sep 25.
5
Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases.1-2 个前哨淋巴结转移的乳腺癌患者 T 分期对腋窝评估方式选择的影响。
Clin Breast Cancer. 2024 Jun;24(4):e232-e243.e1. doi: 10.1016/j.clbc.2024.01.012. Epub 2024 Jan 24.
6
Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer.隐匿性乳腺癌患者的治疗效果和不良预后因素。
Eur J Surg Oncol. 2012 Nov;38(11):1022-8. doi: 10.1016/j.ejso.2012.08.022. Epub 2012 Sep 5.
7
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.腋窝淋巴结清扫术与非腋窝淋巴结清扫术对浸润性乳腺癌伴前哨淋巴结转移女性患者10年总生存率的影响:美国外科医师学会肿瘤学组Z0011(联盟)随机临床试验
JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.
8
Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study.识别新辅助化疗后可能无需进行腋窝淋巴结清扫的ypN1期乳腺癌患者亚组:一项大型队列研究的见解
Breast Cancer. 2025 Mar;32(2):369-384. doi: 10.1007/s12282-024-01663-6. Epub 2024 Dec 27.
9
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.前哨淋巴结活检阳性后接受腋窝淋巴结清扫术的患者乳房切除术后放射治疗的结果
Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):637-44. doi: 10.1016/j.ijrobp.2016.07.003. Epub 2016 Jul 13.
10
The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases.腋窝淋巴结清扫对接受前哨淋巴结微转移先行乳房切除术的乳腺癌患者预后的影响。
Sci Rep. 2025 Mar 27;15(1):10525. doi: 10.1038/s41598-025-91405-1.

引用本文的文献

1
Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.90基因表达检测在隐匿性乳腺癌患者中的临床应用:一例病例报告及文献综述
Breast Cancer. 2025 Jun 5. doi: 10.1007/s12282-025-01728-0.
2
Case report: Unraveling a unique case of male occult breast cancer with axillary intricacies and a comprehensive literature dive.病例报告:剖析一例伴有腋窝复杂情况的男性隐匿性乳腺癌独特病例并全面深入研究文献
Front Oncol. 2025 Feb 11;15:1374032. doi: 10.3389/fonc.2025.1374032. eCollection 2025.
3
Proteomic profiling reveals biological processes and biomarkers involved in the pathogenesis of occult breast cancer.蛋白质组学分析揭示了隐匿性乳腺癌发病机制中涉及的生物学过程和生物标志物。
BMC Cancer. 2025 Feb 10;25(1):231. doi: 10.1186/s12885-025-13657-4.
4
Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes.抗Ri副肿瘤性神经综合征患者的乳腺癌特异性
Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200367. doi: 10.1212/NXI.0000000000200367. Epub 2025 Jan 17.
5
Occult breast cancer in an older woman: A case report.老年女性隐匿性乳腺癌:一例病例报告。
Exp Ther Med. 2024 Dec 24;29(2):38. doi: 10.3892/etm.2024.12788. eCollection 2025 Feb.
6
Locoregional Lymph Node Metastasis from Clinically Occult Breast Cancer: Prognostic Significance of Mastectomy.临床隐匿性乳腺癌的区域淋巴结转移:乳房切除术的预后意义
Breast J. 2024 Aug 9;2024:5878308. doi: 10.1155/2024/5878308. eCollection 2024.
7
Trends in management and related outcomes for occult primary breast cancer.隐匿性原发性乳腺癌的管理趋势及相关结局
Breast Cancer Res Treat. 2025 Jan;209(2):367-374. doi: 10.1007/s10549-024-07500-w. Epub 2024 Oct 13.
8
Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer.腋窝淋巴结清扫术加放射治疗可能是隐匿性乳腺癌患者的最佳治疗策略。
J Natl Cancer Cent. 2022 Sep 24;2(4):198-204. doi: 10.1016/j.jncc.2022.09.001. eCollection 2022 Dec.
9
Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary.女性腋窝淋巴结转移性腺癌或未分化癌不明原发灶的临床病理特征和基因组分析。
J Cancer Res Clin Oncol. 2024 May 15;150(5):256. doi: 10.1007/s00432-024-05783-6.
10
Occult Breast Cancer Presenting as Sternum Pain.以胸骨疼痛为表现的隐匿性乳腺癌
Diagnostics (Basel). 2024 Apr 4;14(7):765. doi: 10.3390/diagnostics14070765.

本文引用的文献

1
Regarding adjuvant radiation therapy in merkel cell carcinoma: selection bias and its affect on overall survival.关于默克尔细胞癌的辅助放射治疗:选择偏倚及其对总生存期的影响。
J Clin Oncol. 2007 Oct 1;25(28):4503-4; author reply 4504-5. doi: 10.1200/JCO.2007.12.2895.
2
Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis.以孤立性腋窝淋巴结转移为表现的隐匿性乳腺癌的预后
Oncology. 2006;71(5-6):456-9. doi: 10.1159/000107111. Epub 2007 Aug 9.
3
Utility of breast magnetic resonance imaging in patients with occult primary breast cancer.乳腺磁共振成像在隐匿性原发性乳腺癌患者中的应用价值。
Ann Surg Oncol. 2005 Dec;12(12):1045-53. doi: 10.1245/ASO.2005.03.520. Epub 2005 Oct 25.
4
Clinical experience with axillary presentation breast cancer.腋窝型乳腺癌的临床经验。
Breast Cancer Res Treat. 2004 Nov;88(1):43-7. doi: 10.1007/s10549-004-9453-9.
5
Retrospective study of women presenting with axillary metastases from occult breast carcinoma.隐匿性乳腺癌伴腋窝转移女性患者的回顾性研究。
World J Surg. 2004 Jun;28(6):535-9. doi: 10.1007/s00268-004-7290-y.
6
Occult primary breast carcinoma presenting as axillary lymphadenopathy.以腋窝淋巴结肿大为表现的隐匿性原发性乳腺癌。
Breast. 2002 Oct;11(5):414-8. doi: 10.1054/brst.2002.0455.
7
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.乳房切除术与保乳治疗早期乳腺癌的18年结果:美国国立癌症研究所随机试验
Cancer. 2003 Aug 15;98(4):697-702. doi: 10.1002/cncr.11580.
8
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.一项比较全乳切除术、乳房肿瘤切除术以及乳房肿瘤切除术加放疗治疗浸润性乳腺癌的随机试验的20年随访。
N Engl J Med. 2002 Oct 17;347(16):1233-41. doi: 10.1056/NEJMoa022152.
9
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.一项比较保乳手术与根治性乳房切除术治疗早期乳腺癌的随机研究的20年随访。
N Engl J Med. 2002 Oct 17;347(16):1227-32. doi: 10.1056/NEJMoa020989.
10
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases.保乳治疗伴有腋窝转移的隐匿性原发性癌的可行性。
Ann Surg Oncol. 2001 Jun;8(5):425-31. doi: 10.1007/s10434-001-0425-6.

基于人群的伴腋窝淋巴结转移隐匿性乳腺癌分析。

Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.

机构信息

Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

出版信息

Cancer. 2010 Sep 1;116(17):4000-6. doi: 10.1002/cncr.25197.

DOI:10.1002/cncr.25197
PMID:20564117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4329781/
Abstract

BACKGROUND

Single-institution data suggest that treatment with radiation and axillary lymph node dissection (ALND) may be an appropriate alternative to mastectomy for T0N+ breast cancer. Population-based multi-institutional data supporting this approach are lacking.

METHODS

The cause-specific survival (CSS) and overall survival (OS) of women with T0N+M0 ductal, lobular, or mixed breast cancer in the Surveillance, Epidemiology, and End Results database from 1983 to 2006 were analyzed. Groups were defined as: 1) no ALND, mastectomy, or RT (observation); 2) ALND only; 3) mastectomy plus ALND with or without postmastectomy radiation (Mast); and 4) breast-conserving therapy (BCT) with ALND and radiation (BCT).

RESULTS

In total, 750 of 770,030 patients with breast cancer had T0N+M0 disease (incidence, 0.10%), and 596 of those patients underwent ALND (79.5%). Patients who underwent Mast or BCT (n = 470) had a 10-year OS rate of 64.9% compared with 58.5% for patients who underwent ALND only (n = 126; P = .02) and 47.5% for patients who underwent observation only (n = 94; P = .04). The 10-year CSS rate was 75.7% for patients who underwent BCT versus 73.9% for patients who underwent Mast (P = .55). In multivariate analysis of CSS for patients who underwent Mast or BCT, the following factors were correlated with an unfavorable outcome: positive estrogen receptor status (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.24-0.96; P = .04), >/=10 positive lymph nodes (HR, 5.7; 95%CI, 2.4-13.4; P </= .01), and <10 resected lymph nodes (HR, 42.9; 95%CI, 1.2-7.1; P = .02). Mast did not improve CSS compared with BCT (HR, 1.09; 95%CI, 0.57-2.1; P = .79).

CONCLUSIONS

Definitive locoregional treatment with either Mast or BCT improved the outcome of patients with T0N+breast cancer, and no difference in survival was observed between the treatments. Cancer 2010. (c) 2010 American Cancer Society.

摘要

背景

单机构数据表明,对于 T0N+乳腺癌,放射治疗和腋窝淋巴结清扫(ALND)联合治疗可能是乳房切除术的一种替代方案。目前缺乏支持这一方法的基于人群的多机构数据。

方法

对 1983 年至 2006 年间监测、流行病学和最终结果数据库中 T0N+M0 导管、小叶或混合乳腺癌女性的特定病因生存率(CSS)和总生存率(OS)进行分析。组定义为:1)无 ALND、乳房切除术或放疗(观察);2)仅 ALND;3)乳房切除术加 ALND 伴或不伴乳房切除术后放疗(Mast);4)保乳治疗(BCT)联合 ALND 和放疗。

结果

总共 770030 例乳腺癌患者中有 750 例(发生率 0.10%)为 T0N+M0 疾病,其中 596 例患者接受了 ALND。接受 Mast 或 BCT(n=470)的患者 10 年 OS 率为 64.9%,而仅接受 ALND(n=126)的患者为 58.5%(P=0.02),仅接受观察的患者为 47.5%(n=94;P=0.04)。接受 BCT 的患者 10 年 CSS 率为 75.7%,而接受 Mast 的患者为 73.9%(P=0.55)。对接受 Mast 或 BCT 的患者进行 CSS 的多变量分析,以下因素与不良结局相关:雌激素受体阳性状态(风险比[HR],0.48;95%置信区间[CI],0.24-0.96;P=0.04)、>10 个阳性淋巴结(HR,5.7;95%CI,2.4-13.4;P=0.01)和<10 个切除淋巴结(HR,42.9;95%CI,1.2-7.1;P=0.02)。与 BCT 相比,Mast 并未改善 CSS(HR,1.09;95%CI,0.57-2.1;P=0.79)。

结论

采用 Mast 或 BCT 进行确定性局部区域治疗可改善 T0N+乳腺癌患者的结局,且两种治疗方法之间的生存率无差异。癌症 2010。(c)2010 年美国癌症协会。